Barriers to use of free antiretroviral therapy in injection drug users.
about
Provider training and experience for people living with HIV/AIDSSetting and organization of care for persons living with HIV/AIDSImproved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimensWomen-specific HIV/AIDS services: identifying and defining the components of holistic service delivery for women living with HIV/AIDSOptimizing care for HIV-infected people who use drugs: evidence-based approaches to overcoming healthcare disparitiesHepatitis C virus infection in san francisco’s HIV-infected urban poorEffects of drug abuse and mental disorders on use and type of antiretroviral therapy in HIV-infected personsThe pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenzLate HIV diagnosis and determinants of progression to AIDS or death after HIV diagnosis among injection drug users, 33 US States, 1996-2004Drug use and receipt of highly active antiretroviral therapy among HIV-infected persons in two U.S. clinic cohortsIllicit drug use is a significant risk factor for loss to follow up in patients with HIV-1 infection at a large urban HIV clinic in TokyoHigh prevalence of illicit drug use in men who have sex with men with HIV-1 infection in JapanGender inequities in quality of care among HIV-positive individuals initiating antiretroviral treatment in British Columbia, Canada (2000-2010)Increases in CD4+ T-cell count at antiretroviral therapy initiation among HIV-positive illicit drug users during a treatment-as-prevention initiative in Canada.Assessing limiting factors to the acceptance of antiretroviral therapy in a large cohort of injecting drug users.Aboriginal status is a prognostic factor for mortality among antiretroviral naïve HIV-positive individuals first initiating HAART.Highly active antiretroviral therapy and hospital readmission: comparison of a matched cohort.Illicit drug use, depression and their association with highly active antiretroviral therapy in HIV-positive womenDelays in protease inhibitor use in clinical practiceEmployment predicts decreased mortality among HIV-seropositive illicit drug users in a setting of universal HIV carePathways to HIV risk and vulnerability among lesbian, gay, bisexual, and transgendered methamphetamine users: a multi-cohort gender-based analysis.Methadone maintenance therapy promotes initiation of antiretroviral therapy among injection drug usersEffectiveness of highly active antiretroviral therapy among injection drug users with late-stage human immunodeficiency virus infectionFemale gender predicts lower access and adherence to antiretroviral therapy in a setting of free healthcareReason and rights in global drug control policy.Suboptimal plasma HIV-1 RNA suppression and adherence among sex workers who use illicit drugs in a Canadian setting: an observational cohort study.Never in care: characteristics of HIV-infected crack cocaine users in 2 US cities who have never been to outpatient HIV careDrug use and barriers to use of health care services.Determinants of hospital admission among HIV-positive people in British Columbia.No evidence of increased sexual risk behaviour after initiating antiretroviral therapy among people who inject drugs.Management of HIV infection in patients with substance use problemsRelationship of injection drug use, antiretroviral therapy resistance, and genetic diversity in the HIV-1 pol genePhysician experience and rates of plasma HIV-1 RNA suppression among illicit drug users: an observational study.Poverty, hunger, education, and residential status impact survival in HIV.Efavirenz therapy in drug users.Predictors of liver-related death among people who inject drugs in Vancouver, Canada: a 15-year prospective cohort study.The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug usersSubstance abuse, adherence with antiretroviral therapy, and clinical outcomes among HIV-infected individuals.The impact of drug use patterns on mortality among polysubstance users in a Canadian setting: a prospective cohort studyDisparities in HIV treatment and physician attitudes about delaying protease inhibitors for nonadherent patients
P2860
Q24236582-03E2A75D-C673-4E91-8225-5BC3B8D5F132Q24245382-8DADB9C6-CA85-4D58-BFE2-BD0CFE556856Q24534391-4EE1E91A-286C-4C60-B0E3-7CF240ACB324Q26851185-4886CBB2-E80C-4C6D-8E12-F917C8FBFFA8Q26865313-D966289C-34A5-404D-9D4F-F8A2C862262CQ27473306-1702DE3B-F494-4669-9557-8568F3C19A11Q28353070-E692298F-1E38-4A88-B2B9-D560819DB07CQ28362277-A37FB935-7F1A-4CF5-8FF0-1455085961F1Q28474749-450DA5FC-3B18-46F4-A9B3-B5DBC362BAC1Q28477883-829BA24C-98EF-4931-9120-D82374AC6372Q28535181-6A588C6E-F9D7-43B9-A5C1-A2FACAAE75D5Q28536725-1519A1B5-CCAC-4B7D-BC06-851FF6A591A2Q28541096-E79CD770-8381-4512-B4A8-1707E03463DCQ30399058-0D572DCF-32FB-4A66-BA37-78673CEB9B2DQ30881919-D51938A7-C364-4F01-8143-6FE46F11C2C9Q33244605-0692D0ED-BB33-4421-9047-B0DB4FF65158Q33259455-9DF6714B-7F3D-4518-9A96-181AA726B4D2Q33563439-392F099A-025E-45F3-A950-182EF1E18411Q33694010-597FD9C1-B440-43A3-8B8B-B974AAF394FAQ33768036-5F9963F0-ADE8-44DD-9FF6-7CD11B8C0ACAQ33788467-5A3153DC-FBB7-46A0-9212-85333022E4CFQ33802147-B958025B-EADC-41EC-BF1D-EFAAD4007CF4Q33834640-C7AC8060-2274-473E-8EA9-370C9D368CBCQ33863309-5202BCDB-6581-44D0-A377-1B039EA5F761Q33895795-23D8D927-A80D-4F1B-B355-D1859C06879AQ33916699-F21C9673-1F4D-423A-AA58-C9D2CDB4E270Q33925086-8B38D760-295C-4EF5-99B2-2644AC725795Q33955883-B79B3EB6-E21F-41C8-B3E5-307105CDE84AQ34034666-D009368A-8F7D-4215-98D0-3B0924683BF9Q34091151-1547FA5E-FD00-427D-A127-D6FE1C24989AQ34113784-9A705D6B-33D6-4FD5-9CDF-CDD7E90B2D87Q34118276-6500585B-E1A8-43B8-9A90-BA3BC30ED993Q34140927-97F74F86-6FF1-43F0-8CF3-A08C95FD5283Q34441490-3CB34E35-63E4-4AFD-8E09-911D98820F2BQ34459338-B52BE45F-CA0A-4D53-B691-EAB9BDF5AA94Q34491134-2DBB8273-17C5-443C-8747-613227F24B59Q34498633-A0649C9B-79B2-4557-A7AD-74C8159188EAQ34524937-28BABB5F-439B-499B-AA47-02B4C866E145Q34582040-69C616B2-3B63-483F-8BE7-1E0552F005BBQ34732022-D83B70B1-F682-49DF-A432-A082501030D5
P2860
Barriers to use of free antiretroviral therapy in injection drug users.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Barriers to use of free antiretroviral therapy in injection drug users.
@en
Barriers to use of free antiretroviral therapy in injection drug users.
@nl
type
label
Barriers to use of free antiretroviral therapy in injection drug users.
@en
Barriers to use of free antiretroviral therapy in injection drug users.
@nl
prefLabel
Barriers to use of free antiretroviral therapy in injection drug users.
@en
Barriers to use of free antiretroviral therapy in injection drug users.
@nl
P2093
P50
P356
P1476
Barriers to use of free antiretroviral therapy in injection drug users.
@en
P2093
J S Montaner
M V O'Shaughnessy
P G Cornelisse
S A Strathdee
P304
P356
10.1001/JAMA.280.6.547
P407
P577
1998-08-01T00:00:00Z